The First $100 Billion Drug
By Ed McKinley
An obesity medication is reportedly poised to shatter the record for pharmaceutical sales volume
A prescription drug that combats obesity is expected to become the biggest-grossing pharmaceutical in history, ringing up five times the sales volume of its nearest competitor, an industry authority predicts.
“With modest patient penetration, we could see tirzepatide generating more than $100 billion in sales annually” for drug manufacturer Eli Lilly & Co. (LLY), says Bank of America analyst Geoffery Meacham.
That would dwarf the one-year record of $21 billion in sales that the anti-inflammatory drug Humira posted in 2021 for its maker, AbbVie (ABBV). But a tirzepatide juggernaut seems likely, partly because the medication could...
Topics
-
Tired of Gold? We Could Give You Some Crypto Instead.
By Ed McKinley
|Inside Trump’s movement to create the new Fort Knox: a digital strategic reserve for Bitcoin and perhaps other tokens -
Nvidia’s Q4 Earnings: The Promise of AI Meets the Perils of Overconcentration
|The company’s AI-driven growth looks great, but does its future depend too much on data centers? Here are two takeaways from earnings. -
As Strong as Fort Knox
By Ed McKinley
|Trump and Musk want to check out one of the most secure locations in America: the United States Bullion Depository -
Letter to the Editor: Musk, Governance and America’s Future
By Luckbox
|Also, the article "Democracy in the Exponential Age," below. -
Are Robotaxis Really Driving Themselves?
By Ed McKinley
|Not quite. But with a little help from remote nannies they’re racking up impressive safety records. -
The $44 Billion Twitter ‘Catastrophe’ That Wasn’t: Musk’s Stunning Financial Turnaround at X
By Jeff Joseph
|The little-known story of how X doubled Twitter's best profits while the experts predicted "disaster” -
Waymo’s Road to IPO: Hidden Value for Alphabet Investors
|The ride-hailing company is shaking up the industry with its trailblazing autonomous driving technology -
Common Cents Dictates Some Penny-Wise Moves
By Ed McKinley
|President Trump wants to stop minting the one-cent piece, and there’s not much dissent -
Wall Street Yawns, Main Street Pays: Decoding Trump’s Trade Theater
By Ed McKinley
|Everybody talks economics when the subject of import duties comes up—that makes sense. But they’re also a powerful bargaining chip in any type of international negotiation. -
Salesforce’s New AI Push Could Transform Its Growth Trajectory
By Jeff Joseph
|The company’s ”AI agents" automate complex tasks, like answering customers’ questions -
Trends & Tickers: My Four Favorite Trade Ideas for 2025
|These are the most compelling investment themes I see for the coming year—just don’t forget the risks -
Argentina’s Economic Success: Can U.S. Learn from Milei’s Reforms?
|The U.S. faces tough fiscal choices, and Argentina’s bold reforms may provide a blueprint. -
Trump’s Panama Canal Controversy: High Tolls, Tariffs and Trade Wars
|Trump’s Panama Canal talk stirs the pot, but his proposed tariffs could really stir the markets -
Quantum Computing Is the Future—Here’s How to Invest
|From science fiction to reality—quantum computing is poised to emerge as the next big thing in tech. Why QTUM Is Your Ticket to the Future -
Will RFK Jr. Transform the Way America Makes and Sells Food?
|Politics may change the recipe for success in the food industry. Here are some potential winners and losers. -
GLP-1, the FDA and RFK-J Take on the Food Biz
By Ed McKinley
|Junk food manufacturers and restaurant owners are trying to adjust to three looming challenges -
Mark Zuckerberg 2.0: Superficial Makeover or Profound Change of Heart?
By Ed McKinley
|The billionaire CEO of Meta Platforms is shedding his dour image. We ask why. -
What Would Chris Wright’s Confirmation Mean for Nuclear Power?
By Ed McKinley
|The nominee for secretary of energy owns stock worth $40 million in an oil and gas services company -
What Higher Tariffs Would Mean for Markets and Consumers
|Stiff proposed import duties could raise prices and might even foment trade wars -
This Bubble’s Not in Trouble: Why the 2024 Bull Run Isn’t Ready to Quit
|From AI to tax cuts—here's why this rally might be just getting started